Biontech Se

This study is testing a new mpox vaccine made with mRNA technology, similar to some COVID-19 vaccines. It aims to see if the vaccine is safe and if it triggers a strong immune response in healthy adults, both those who have and have not been exposed to related viruses before. Abo…

This study is testing updated versions of the Pfizer-BioNTech COVID-19 vaccine in healthy children from 6 months to 12 years old. It aims to check the safety, side effects, and how well the body's immune system responds to these new shots. The trial includes children who have nev…

This study aims to see how safe and effective an updated COVID-19 vaccine is for healthy adults between 50 and 64 years old. About 25,500 participants will be randomly assigned to receive either the new vaccine or a placebo (a shot with no active ingredient). Researchers will com…

This large Phase 3 trial is testing whether a new drug called pumitamig (BNT327), when added to standard chemotherapy, works better than the current standard treatment (atezolizumab plus chemotherapy) for people newly diagnosed with extensive-stage small-cell lung cancer. The stu…

This study is testing a combination of two new drugs, called BNT326 and BNT327, for people with advanced non-small cell lung cancer (NSCLC). The main goals are to find safe doses and see if the combination can help shrink tumors or control the cancer's growth. It will enroll abou…

This study is testing a new drug called BNT326, both by itself and in combination with other cancer immunotherapies, for people with advanced solid tumors that have spread or returned after prior treatment. The main goals are to find the safest and most effective dose and to see …

This study is testing whether adding an experimental drug called pumitamig (BNT327) to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer. It will involve about 105 adults who have not yet received treatment for their advanced cancer. The main go…

This early-stage study is testing a new drug called BNT329 in people with advanced solid cancers that have a specific marker called CA19-9. The main goals are to find the safest dose and see if the drug causes tumors to shrink or stop growing. The trial is for patients whose canc…

This early-stage study is testing the safety and initial effectiveness of two new cancer drugs, BNT3212 alone and combined with BNT327. It is for adults with advanced solid tumors who have no other standard treatments left. The main goals are to find safe doses and see if the dru…

This study is testing a new combination of two drugs, called BNT323 and BNT327, for people with advanced breast cancer that has spread or cannot be removed by surgery. The first part of the study aims to find the safest and most effective dose. The second part will compare how we…

This global study is testing whether adding a new investigational drug called BNT327 (pumitamig) to standard chemotherapy works better for people newly diagnosed with advanced non-small cell lung cancer. It will involve about 1,260 participants and has two parts: first to check s…

This study is testing whether a personalized cancer vaccine (RO7198457) can prevent cancer from returning in patients who have had surgery for stage II or III colorectal cancer and still have traces of cancer DNA in their blood. The trial will compare the vaccine against a 'watch…

This study is testing whether adding an experimental drug called pumitamig to standard chemotherapy helps control advanced non-small cell lung cancer that has worsened after initial treatment. It will involve about 60 people with this type of cancer. The first part checks the saf…

This study is testing whether two new immune-boosting drugs (BNT314 and BNT327) work better when added to standard chemotherapy for advanced colorectal cancer that has spread. Researchers will enroll 482 people whose cancer didn't respond well to initial treatment or who haven't …

This is the first human study of a new cancer drug called BNT317, developed by BioNTech. It will test the safety and find the right dose for patients with advanced solid tumors who have run out of standard treatment options. The study will enroll 39 participants and follow them f…

This trial is testing whether adding a new drug called BNT113 to a standard immunotherapy (pembrolizumab) works better than the standard treatment alone for people with advanced head and neck cancer linked to HPV16. It aims to see if the combination helps patients live longer and…

This is the first human trial of an experimental drug called BNT116 for people with advanced non-small cell lung cancer. The main goal is to find safe doses when BNT116 is given alone and when combined with other approved or experimental cancer drugs. The study will enroll about …

This study is testing a new drug called BNT323 for women whose endometrial (uterine) cancer has returned after previous treatments, including immunotherapy. It will compare BNT323 against standard chemotherapy to see which is better at controlling the cancer and helping patients …

This study is testing the safety and effectiveness of a new drug called pumitamig, both alone and in combination with other cancer drugs, for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. The goal is to see if these treatments can shrin…

This study is testing a new combination of two experimental drugs, BNT324 and BNT327, for people with advanced small cell or non-small cell lung cancer. The main goals are to find the safest and most effective dose of the drug combination and to see if it helps shrink tumors. The…

This is a first-in-human study to test the safety and blood levels of a new antibody called BNT351. It will involve 61 adults, both with and without HIV, to see if the antibody is safe and if it can reduce the amount of HIV in the blood of those living with the virus. The study i…

This study is testing whether adding an experimental drug called BNT327 to standard chemotherapy works better than chemotherapy alone for advanced triple-negative breast cancer. The trial will involve 558 patients whose cancer has returned or spread and who can't receive standard…